Cumberland Pharmaceuticals Announces Positive Results from Phase 2 FIGHT DMD Trial of Ifetroban for Treatment of Duchenne Cardiomyopathy ...
Introducing PPMD’s Dystrophinopathy Clinical Research Network (DCRN): Advancing the Research Evolution ...
Avidity Biosciences Announces Plans to File Biologics License Application for Delpacibart Zotadirsen (AOC 1044) ...